$NVAX offers a great short squeeze opportunity with SI at 55% and a high volume breakout - it take 9 days to cover!!

NVAX offers an attractive short-squeeze setup, with roughly 55\*\*% of its float sold short\*\* and about **9 days to cover**. Strong upward momentum and elevated volume could force additional short covering.

**Sanofi COVID/flu combination vaccine — potentially the biggest near-term catalyst.**
Sanofi is in advanced discussions with regulators on the timing of a Phase 3 COVID/flu combination trial. **Starting that Phase 3 trial would trigger a $125 million milestone payment to Novavax.** There is another potential **$225 million launch milestone** later.

**Risk:** Exit if the breakout fails and momentum reverses.

**Preferred strategy:** Use call options to limit downside risk and multiply your long trade with massive leverage.